AnteoTech Limited Stock

Equities

ADO

AU000000ADO8

Biotechnology & Medical Research

Delayed Australian S.E. 01:02:00 2024-05-22 am EDT 5-day change 1st Jan Change
0.026 AUD +18.18% Intraday chart for AnteoTech Limited +18.18% -27.78%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2022 761K 507K Sales 2023 366K 244K Capitalization 82M 54.68M
Net income 2022 -10M -6.67M Net income 2023 -12M -8M EV / Sales 2022 158 x
Net cash position 2022 9.07M 6.05M Net cash position 2023 1.41M 943K EV / Sales 2023 220 x
P/E ratio 2022
-12 x
P/E ratio 2023
-6.33 x
Employees 99
Yield 2022 *
-
Yield 2023
-
Free-Float 93.01%
More Fundamentals * Assessed data
Dynamic Chart
1 day+18.18%
1 week+18.18%
Current month+23.81%
1 month+13.04%
3 months-21.21%
6 months-10.34%
Current year-27.78%
More quotes
1 week
0.02
Extreme 0.021
0.03
1 month
0.02
Extreme 0.02
0.03
Current year
0.02
Extreme 0.02
0.04
1 year
0.02
Extreme 0.02
0.06
3 years
0.02
Extreme 0.02
0.42
5 years
0.01
Extreme 0.01
0.50
10 years
0.01
Extreme 0.008
0.50
More quotes
Managers TitleAgeSince
Founder - 08-12-31
Chief Executive Officer - 22-10-03
Director of Finance/CFO - 23-08-27
Members of the board TitleAgeSince
Director/Board Member - 21-08-31
Director/Board Member - 21-08-31
Chief Executive Officer - 22-10-03
More insiders
Date Price Change Volume
24-05-22 0.026 +18.18% 18 200 997
24-05-21 0.022 0.00% 2,765,061
24-05-20 0.022 -4.35% 1,224,884
24-05-17 0.023 +4.55% 316,006
24-05-16 0.022 0.00% 732,872

Delayed Quote Australian S.E., May 22, 2024 at 01:02 am EDT

More quotes
AnteoTech Limited is an Australia-based company engaged in providing solutions for the clean energy and life sciences markets using applied materials technology. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Company’s lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The Company has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.
Calendar
More about the company

Annual profits - Rate of surprise

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW